acute myeloid leukemia-free survival
The group of patients treated for > 4 cycles achieved a higher ORR, CR, time overall survival (OS), progression-free (PFS), acute myeloid leukemia-free survival (AMLFS) more than those treated with ≤ 4 cycles (p respectively: p = 0.032; 0.009; 0.007; 0.01; 0.009).
The group of patients treated for > 4 cycles achieved a higher ORR, CR, time overall survival ( OS ), progression-free ( PFS ), acute myeloid leukemia-free survival ( AMLFS ) more than those treated with ≤ 4 cycles ( p respectively : p = 0 .032; 0 .009; 0 .007; 0 .01; 0 .009 ) .